Unfortunately, a tau-directed therapeutic that preserves the structure and function of the perforant pathway has not been identified yet, a conspicuous omission given its importance to certain forms of long-term memory, preferential susceptibility in early-stage AD, and potential to spread tau pathology to limbic and neocortical regions. This evidence concerns the gene MAPT and Alzheimer disease.